跳至主要内容
临床试验/NCT00241072
NCT00241072已完成4 期

A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt)

Novartis0 个研究点目标入组 27 人开始时间: 2002年9月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
27
主要终点
Change from baseline insulin sensitivity after 24 weeks

研究概览

简要总结

THE PURPOSE OF THIS STUDY IS TO DETERMINE IF 24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG) IMPROVES INSULIN SENSITIVITY IN SUBJECTS WITH HIGHER THAN NORMAL GLUCOSE LEVELS USING A TEST CALLED THE EUGLYCEMIC CLAMP.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • history or presenting hypertension Elevated fasting blood glucose levels -

排除标准

  • Pregnancy potential Diabetes mellitus
  • Other criteria apply

结局指标

主要结局

Change from baseline insulin sensitivity after 24 weeks

次要结局

  • Change from baseline in the function of cells that line blood vessels after 24 weeks
  • Change from baseline in markers of vascular inflammation after 24 weeks
  • Adverse events and serious adverse events at each study visit for 24 weeks
  • Hematology, blood chemistries, and urine measurements for up to 24 weeks
  • Vital signs and physical examinations for up to 24 weeks

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

相似试验

Clinical Trial To Evaluate The Effect Of Valsartan... | 临床试验